![]() One obvious factor in Israel’s success has been the presence of a mass vaccination plan. Yet, some other countries also have these advantages, to a greater or lesser degree, and they have not been so successful. Also, its population density is relatively high, avoiding the need for very complex logistical arrangements to reach outlying areas. It also has a relatively young population, making it easier to deliver a policy that prioritises older people. With only 9.3 million people, it requires only a very small share of the world production of vaccine. In this brief commentary, and drawing on the experiences of European countries in the COVID-19 response so far, we seek to draw some lessons.Īs Rosen and colleagues note, Israel has some intrinsic advantages. So what can we learn from the Israeli experience? In the accompanying paper, Rosen and colleagues set out a series of reasons why Israel has been so successful. Meanwhile, other countries, including the United States and many in Europe, are struggling to get their vaccination programs off the ground, with many accounts of doses going to waste from missed appointments or dosing challenges. As governments across the world race to roll out vaccination programmes against COVID-19, many are looking to Israel to understand how it has led the way, administering a first dose of the Pfizer-BioNtech vaccine to over 1 in 10 Israelis within 2 weeks of its approval.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |